ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,821 to 4,840 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Linagliptin 5 mg vs Placebo: serious adverse events87 of 631

83 of 630

0.6 points

-3.2 to 4.4

1,261NCT00954447

Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Preoxygenation With Non-Invasive Positive Pressure Ventilation Group vs Preoxygenation With Facemask Oxygen Group: Incidence of Very Severe Hypoxemia15 of 624

36 of 637

-3.2 points

-5.5 to -1.1

1,261NCT05267652

Pragmatic Trial Examining Oxygenation Prior to Intubation

Preoxygenation With Non-Invasive Positive Pressure Ventilation Group vs Preoxygenation With Facemask Oxygen Group: Incidence of Hypoxemia57 of 624

118 of 637

-9.4 points

-13.2 to -5.6

1,261NCT05267652

Pragmatic Trial Examining Oxygenation Prior to Intubation

Preoxygenation With Non-Invasive Positive Pressure Ventilation Group vs Preoxygenation With Facemask Oxygen Group: Incidence of Severe Hypoxemia39 of 624

84 of 637

-6.9 points

-10.2 to -3.7

1,261NCT05267652

Pragmatic Trial Examining Oxygenation Prior to Intubation

Arm I (Chemo +/- Bevacizumab) vs Arm II (Chemo, Cetuximab, +/- Bevacizumab): serious adverse events66 of 632

97 of 627

-5.0 points

-8.8 to -1.3

1,259NCT00946712

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

LHRHa + TAK-700 vs LHRHa + Bicalutamide: serious adverse events235 of 627

15 of 629

35.1 points

31.1 to 39.1

1,256NCT01809691

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

Best Practice Clinic-Based Care vs Telehealth Care: Number of Participants Reporting High Confidence in Knowing BP Target Numbers at Six Months437 of 662

465 of 594

-12.3 points

-17.1 to -7.3

1,256NCT02996565

Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure

Semaglutide vs Standard of Care: deaths from any cause9 of 634

9 of 621

-0.0 points

-1.5 to 1.4

1,255NCT03596450

Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

Semaglutide vs Standard of Care: serious adverse events38 of 634

39 of 621

-0.3 points

-3.0 to 2.4

1,255NCT03596450

Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

Napabucasin + FOLFIRI ± Bevacizumab vs FOLFIRI ± Bevacizumab: deaths from any cause507 of 624

499 of 629

1.9 points

-2.5 to 6.3

1,253NCT02753127

A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer

Long Term Medication Assisted Treatment (LT-MAT) vs Short Term Medication Assisted Treatment (ST-MAT): serious adverse events38 of 623

42 of 628

-0.6 points

-3.3 to 2.2

1,251NCT00270257

Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users

Pembrolizumab vs Chemotherapy (SOC Treatment): Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)126 of 636

93 of 615

4.7 points

0.5 to 8.9

1,251NCT02220894

Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)

Pembrolizumab vs Chemotherapy (SOC Treatment): Number of Participants Who Experienced At Least One Adverse Event (AE)608 of 636

606 of 615

-2.9 points

-4.9 to -1.1

1,251NCT02220894

Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)

Pembrolizumab + Enzalutamide + ADT vs Placebo + Enzalutamide + ADT: deaths from any cause105 of 626

93 of 625

1.9 points

-2.2 to 5.9

1,251NCT04191096

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

PFC Sigma PS TKA (Total Knee Arthroplasty) vs PFC Sigma HP PS TKA (Total Knee Arthroplasty): serious adverse events45 of 625

29 of 625

2.6 points

-0.1 to 5.2

1,250NCT01340144

Evaluation of Patellar Crepitus Following Total Knee Arthroplasty

GFRS EPD vs GEF EPD: Major Adverse Events (MAE)18 of 386

36 of 864

0.5 points

-1.8 to 3.3

1,250NCT01343667

GORE Flow Reversal System and GORE Embolic Filter Extension Study

Telehealth Palliative Care: Patients vs In-person Palliative Care: Patients: deaths from any cause365 of 633

368 of 617

-2.0 points

-7.4 to 3.5

1,250NCT03375489

Early Integrated Telehealth Versus In-Person Palliative Care for Patients With Lung Cancer

HIV Positive vs HIV Negative: High Risk (hr)-Human Papillomavirus (HPV) Positive Rate295 of 625

181 of 625

18.2 points

12.9 to 23.4

1,250NCT04092257

HPV-Based Screen-and-Treat Demonstration Project in Lilongwe

Pembrolizumab + Enzalutamide + ADT vs Placebo + Enzalutamide + ADT: serious adverse events252 of 625

145 of 625

17.1 points

12.0 to 22.1

1,250NCT04191096

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

Dapagliflozin 10mg vs Placebo: Improving Clinical Recovery: Hierarchical Composite Outcome Measure Including Death From Any Cause Through Day 30, New/Worsened Organ Dysfunction, Clinical Status at Day 30 and Hospital Discharge Before Day 30 and Alive at Day 30.547 of 625

532 of 625

2.4 points

-1.4 to 6.2

1,250NCT04350593

Dapagliflozin in Respiratory Failure in Patients With COVID-19

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=242"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=242

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00954447-sae",
        "title": "Linagliptin 5 mg vs Placebo: serious adverse events",
        "summary": "87 of 631 against 83 of 630; risk difference 0.6 points, 95% interval -3.2 to 4.4; NCT00954447, Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes",
        "record": "/library/comparisons/NCT00954447-sae",
        "nct_id": "NCT00954447",
        "kind": "serious-adverse-events",
        "participants": 1261,
        "risk_difference": {
          "value": 0.006130354941765392,
          "lower": -0.031713044080248616,
          "upper": 0.04397310913567905
        },
        "group_1": "87 of 631",
        "group_2": "83 of 630",
        "difference": "0.6 points",
        "interval": "-3.2 to 4.4",
        "trial_title": "Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes"
      },
      {
        "id": "NCT05267652-1bd84381",
        "title": "Preoxygenation With Non-Invasive Positive Pressure Ventilation Group vs Preoxygenation With Facemask Oxygen Group: Incidence of Very Severe Hypoxemia",
        "summary": "15 of 624 against 36 of 637; risk difference -3.2 points, 95% interval -5.5 to -1.1; NCT05267652, Pragmatic Trial Examining Oxygenation Prior to Intubation",
        "record": "/library/comparisons/NCT05267652-1bd84381",
        "nct_id": "NCT05267652",
        "kind": "outcome",
        "participants": 1261,
        "risk_difference": {
          "value": -0.03247645211930926,
          "lower": -0.05524824227990783,
          "upper": -0.010797422640163156
        },
        "group_1": "15 of 624",
        "group_2": "36 of 637",
        "difference": "-3.2 points",
        "interval": "-5.5 to -1.1",
        "trial_title": "Pragmatic Trial Examining Oxygenation Prior to Intubation"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=243",
  "request_id": "5NZfF8xlvCYte_J8"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Instruments

The conductscience.com catalog

One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

Diseases

Open Targets

One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.

Companies

ClinicalTrials.gov

One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.

Cell lines

Cellosaurus

One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.

Journal index

PubMed and NLM's journal list

One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?